Media & Investors

Corporate Profile

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

Stock Quote


Copyright Nasdaq. Minimum 15 minutes delayed.

In the Media

Jun 18, 2019
Calithera’s positive ENTRATA Phase 2 study demonstrating the benefit of telaglenastat in combination with everolimus in treating RCC is discussed in this June 2019 OncLive article
Jun 17, 2019
Industry news source SCRIP discusses data from the ENTRATA trial and its proof-of-concept implications for Calithera’s lead compound, telaglenastat.

Upcoming Events

More events are coming soon.